DK0841929T3 - Quinoloner og deres terapeutiske anvendelse - Google Patents

Quinoloner og deres terapeutiske anvendelse

Info

Publication number
DK0841929T3
DK0841929T3 DK96925905T DK96925905T DK0841929T3 DK 0841929 T3 DK0841929 T3 DK 0841929T3 DK 96925905 T DK96925905 T DK 96925905T DK 96925905 T DK96925905 T DK 96925905T DK 0841929 T3 DK0841929 T3 DK 0841929T3
Authority
DK
Denmark
Prior art keywords
quinolones
compounds
therapeutic use
mixtures
formula
Prior art date
Application number
DK96925905T
Other languages
English (en)
Inventor
Steven Colin Beasley
John Gary Montana
Hazel Joan Dyke
Alan Findlay Haughan
Karen Ann Runcie
David Thomas Manallack
George Martin Buckley
Hannah Jayne Kendall
Andrew Douglas Baxter
Robert James Maxey
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515811.9A external-priority patent/GB9515811D0/en
Priority claimed from GBGB9526377.8A external-priority patent/GB9526377D0/en
Priority claimed from GBGB9605868.0A external-priority patent/GB9605868D0/en
Priority claimed from GBGB9611898.9A external-priority patent/GB9611898D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0841929T3 publication Critical patent/DK0841929T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
DK96925905T 1995-08-02 1996-08-02 Quinoloner og deres terapeutiske anvendelse DK0841929T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9515811.9A GB9515811D0 (en) 1995-08-02 1995-08-02 Novel compounds
GBGB9526377.8A GB9526377D0 (en) 1995-12-22 1995-12-22 Novel compounds
GBGB9605868.0A GB9605868D0 (en) 1996-03-20 1996-03-20 Novel compounds
GBGB9611898.9A GB9611898D0 (en) 1996-06-07 1996-06-07 Quinolones and their therapeutic use
PCT/GB1996/001862 WO1997004779A1 (en) 1995-08-02 1996-08-02 Quinolones and their therapeutic use

Publications (1)

Publication Number Publication Date
DK0841929T3 true DK0841929T3 (da) 2003-09-01

Family

ID=27451319

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96925905T DK0841929T3 (da) 1995-08-02 1996-08-02 Quinoloner og deres terapeutiske anvendelse

Country Status (12)

Country Link
US (1) US5891878A (da)
EP (1) EP0841929B1 (da)
JP (1) JPH11513021A (da)
AT (1) ATE239477T1 (da)
AU (1) AU696390B2 (da)
CA (1) CA2225552A1 (da)
DE (1) DE69628019T2 (da)
DK (1) DK0841929T3 (da)
ES (1) ES2193252T3 (da)
MX (1) MX9800922A (da)
PT (1) PT841929E (da)
WO (1) WO1997004779A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
IT1296985B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
EP1042295B1 (en) * 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
CA2399741A1 (en) 2000-03-21 2001-11-01 Scott D. Larsen 4-hydroxycinnoline-3-carboxyamides as antiviral agents
NZ521523A (en) 2000-03-21 2004-05-28 Upjohn Co 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
KR20020093849A (ko) 2000-03-21 2002-12-16 파마시아 앤드 업존 캄파니 항바이러스제로서의4-옥소-1,4-디히드로[1,8]나프티리딘-3-카르복스아미드
KR20020081479A (ko) 2000-03-21 2002-10-26 파마시아 앤드 업존 캄파니 항바이러스제인4-옥소-1,4-디히드로-3-신놀린카르복스아미드
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
WO2002070487A1 (en) 2001-03-01 2002-09-12 Pharmacia & Upjohn Company Substituted quinolinecarboxamides as antiviral agents
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
PT1490392E (pt) * 2002-04-01 2007-04-30 Univ Florida Quinóis esteroidais como pró-fármacos de antioxidantes
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
US7300926B2 (en) * 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
WO2004069248A1 (en) * 2002-12-09 2004-08-19 University Of Florida Prodrugs for use a ophthalmic agents
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
EP2502912A3 (en) * 2004-06-24 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RU2525115C2 (ru) * 2004-06-24 2014-08-10 Вертекс Фармасьютикалз Инкорпорейтед Способ модуляции транспортеров атф-связывающей кассеты
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DE102004035203A1 (de) * 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone
DE102005030524A1 (de) 2005-06-30 2007-01-18 Aicuris Gmbh & Co. Kg Substituierte Chinolone II
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
AU2006331565A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
MX2011004375A (es) 2008-10-23 2013-03-07 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107998131B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯类化合物用于制备抗adv-7病毒药物
CN111646941A (zh) * 2020-07-17 2020-09-11 天津科技大学 一种磺酰胺类衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524558A (en) * 1967-03-30 1970-08-18 American Mach & Foundry Cargo loading means and method
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
FR2564832B1 (fr) * 1984-05-23 1987-05-15 Panmedica Sa Nouveaux n-acyl derives d'amino-acides et leurs esters, leur procede de preparation et medicaments les contenant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
JPH02124871A (ja) * 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体

Also Published As

Publication number Publication date
AU696390B2 (en) 1998-09-10
EP0841929B1 (en) 2003-05-07
US5891878A (en) 1999-04-06
WO1997004779A1 (en) 1997-02-13
EP0841929A1 (en) 1998-05-20
DE69628019D1 (de) 2003-06-12
PT841929E (pt) 2003-09-30
DE69628019T2 (de) 2004-01-22
ES2193252T3 (es) 2003-11-01
ATE239477T1 (de) 2003-05-15
MX9800922A (es) 1998-05-31
JPH11513021A (ja) 1999-11-09
CA2225552A1 (en) 1997-02-13
AU6626396A (en) 1997-02-26

Similar Documents

Publication Publication Date Title
PT841929E (pt) Quinolonas e sua utilizacao terapeutica
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
GB9801690D0 (en) Therapeutic agents
MXPA04007470A (es) Piridinonas sustituidas.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
DK0636025T3 (da) Forbindelser, der er egnede til behandling af allergiske og inflammatoriske sygdomme
ATE165830T1 (de) Dihydro pyrazolopyrrole
ATE258437T1 (de) Chinolone und deren therapeutische verwendung
AU2002246728A1 (en) Carboline derivatives
DK0944616T3 (da) Bicykliske arylcarboxamider og deres terapeutiske anvendelse
WO2001017963A3 (en) Aminoalkoxy carbazoles and their use as 5-ht ligands
NO992770L (no) Nye heterocyklisk substituerte benzamider og deres anvendelse ved bekjempelse av sykdommer
AU2002213421A1 (en) Condensed pyridoindole derivatives
AU2002249890A1 (en) Carboline derivatives
NO954328D0 (no) Nye substituerte 1-fenyl-pyridinyl-benzotriazoler
DE69823493D1 (de) Tetrahydropyridoverbindungen
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
MXPA04005809A (es) Inhibidores de proteinas quinasas.
UY27587A1 (es) Heterociclos terapéuticos
MY106522A (en) Arylaminocarbonyl compounds.
MXPA02001204A (es) Compuestos calciliticos.
ES2104174T3 (es) Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität